SSRI use and risk of fractures among perimenopausal women without mental disorders

Injury Prevention

Volumn 21, Issue 6, 2015, Pages 397-403

  Sheu, Yi Han ^a   Lanteigne, Amy ^a   Stürmer, Til ^b   Pate, Virginia ^b   Azrael, Deborah ^a   Miller, Matthew ^a,c  

^a HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^b University of North Carolina at Chapel Hill   (United States)

^c NORTHEASTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

SEROTONIN UPTAKE INHIBITOR;

ADULT; BONE DENSITY; CLIMACTERIUM; COHORT ANALYSIS; FEMALE; FRACTURES, BONE; HOT FLASHES; HUMAN; MENTAL DISEASE; MIDDLE AGED; REGRESSION ANALYSIS; RISK FACTOR; UNITED STATES;

ADULT; BONE DENSITY; COHORT STUDIES; FEMALE; FRACTURES, BONE; HOT FLASHES; HUMANS; MENTAL DISORDERS; MIDDLE AGED; PERIMENOPAUSE; REGRESSION ANALYSIS; RISK FACTORS; SEROTONIN UPTAKE INHIBITORS; UNITED STATES;

EID: 84948129449     PISSN: 13538047     EISSN: 14755785     Source Type: Journal    
DOI: 10.1136/injuryprev-2014-041483     Document Type: Article

References (35)

1. APA.Practice Guideline for the treatment of patients with major depressive disorder. 3rd edn. American Psychiatric Association, 2010.
2. CANMAT. Clinical Guidelines for the management of major depressive disorder in adults. Canadian Network for Mood and Anxiety Treatments, 2009.
3. NICE. The NICE Guideline on the treatment and management of depression in adults. National Institute for Health and Clinical Excellence, 2009.
4. Mercier A, Auger-Aubin I, Lebeau JP, et al. Evidence of prescription of antidepressants for non-psychiatric conditions in primary care: an analysis of guidelines and systematic reviews. BMC Fam Practice 2013;14:55.
5. Mojtabai R, Olfson M. Proportion of antidepressants prescribed without a psychiatric diagnosis is growing. Health Aff 2011;30:1434–42.
6. Orleans RJ, Li L, Kim MJ, et al. FDA approval of paroxetine for menopausal hot flushes. N Engl J Med 2014;370:1777–9.
7. Barton DL, Loprinzi CL, Novotny P, et al. Pilot evaluation of citalopram for the relief of hot flashes. J Supportive Oncol 2003;1:47–51.
8. Carpenter JS, Guthrie KA, Larson JC, et al. Effect of escitalopram on hot flash interference: a randomized, controlled trial. Fertil Steril 2012;97:1399–404.
9. Freeman EW, Guthrie KA, Caan B, et al. Efficacy of escitalopram for hot flashes in healthy menopausal women: a randomized controlled trial. JAMA 2011;305:267–74.
10. Loprinzi CL, Sloan JA, Perez EA, et al. Phase III evaluation of fluoxetine for treatment of hot flashes. J Clin Oncol 2002;20:1578–83.
11. Shams T, Firwana B, Habib F, et al. SSRIs for hot flashes: a systematic review and meta-analysis of randomized trials. J Gen Intern Med 2014;29:204–13.
12. Soares CN, Poitras JR, Prouty J, et al. Efficacy of citalopram as a monotherapy or as an adjunctive treatment to estrogen therapy for perimenopausal and postmenopausal women with depression and vasomotor symptoms. J Clin Psychiatry 2003;64:473–9.
13. Ensrud KE, Joffe H, Guthrie KA, et al. Effect of escitalopram on insomnia symptoms and subjective sleep quality in healthy perimenopausal and postmenopausal women with hot flashes: a randomized controlled trial. Menopause 2012;19:848–55.
14. Handley AP, Williams M. The efficacy and tolerability of SSRI/SNRIs in the treatment of vasomotor symptoms in menopausal women: a systematic review. J Am Assoc Nurse Pract 2015;27:54–61.
15. Grady D. Clinical practice: management of menopausal symptoms. N Engl J Med 2006;355:2338–47.
16. Pachman DR, Jones JM, Loprinzi CL. Management of menopause-associated vasomotor symptoms: current treatment options, challenges and future directions. Int J Women’s Health 2010;2:123–35.
17. Mezuk B, Eaton WW, Golden SH. Depression and osteoporosis: epidemiology and potential mediating pathways. Osteoporos Int 2008;19:1–12.
18. O’Brien SM. A possible role of recurrent major depression in risk of fracture. Arch Intern Med 2007;167:2370.
19. Curtis JR, Mudano AS, Solomon DH, et al. Identification and validation of vertebral compression fractures using administrative claims data. Med Care 2009;47:69–72.
20. Cadarette SM, Katz JN, Brookhart MA, et al. Relative effectiveness of osteoporosis drugs for preventing nonvertebral fracture. Ann Intern Med 2008;148:637–46.
21. Sato T, Matsuyama Y. Marginal structural models as a tool for standardization. Epidemiology 2003;14:680–6.
22. Diem SJ, Blackwell TL, Stone KL, et al. Use of antidepressant medications and risk of fracture in older women. Calcif Tissue Int 2011;88:476–84.
23. Eom CS, Lee HK, Ye S, et al. Use of selective serotonin reuptake inhibitors and risk of fracture: a systematic review and meta-analysis. J Bone Miner Res 2012;27:1186–95.
24. Moura C, Bernatsky S, Abrahamowicz M, et al. Antidepressant use and 10-year incident fracture risk: the population-based Canadian Multicentre Osteoporosis Study (CaMoS). Osteoporos Int 2014;25:1473–81.
25. Rabenda V, Nicolet D, Beaudart C, et al. Relationship between use of antidepressants and risk of fractures: a meta-analysis. Osteoporos Int 2013;24:121–37.
26. Verdel BM, Souverein PC, Egberts TC, et al. Use of antidepressant drugs and risk of osteoporotic and non-osteoporotic fractures. Bone 2010;47:604–9.
27. Ziere G, Dieleman JP, van der Cammen TJ, et al. Selective serotonin reuptake inhibiting antidepressants are associated with an increased risk of nonvertebral fractures. J Clin Psychopharmacol 2008;28:411–17.
28. Zucker I, Chodick G, Grunhaus L, et al. Adherence to treatment with selective serotonin reuptake inhibitors and the risk for fractures and bone loss: a population-based cohort study. CNS Drugs 2012;26:537–47.
29. Bab I, Yirmiya R. Depression, selective serotonin reuptake inhibitors, and osteoporosis. Curr Osteoporos Rep 2010;8:185–91.
30. Kwok CS, Yeong JK, Loke YK. Meta-analysis: risk of fractures with acid-suppressing medication. Bone 2011;48:768–76.
31. Vestergaard P, Rejnmark L, Mosekilde L. Proton pump inhibitors, histamine H2 receptor antagonists, and other antacid medications and the risk of fracture. Calcif Tissue Int 2006;79:76–83.
32. Yu EW, Bauer SR, Bain PA, et al. Proton pump inhibitors and risk of fractures: a meta-analysis of 11 international studies. Am J Med 2011;124:519–26.
33. Ngamruengphong S, Leontiadis GI, Radhi S, et al. Proton pump inhibitors and risk of fracture: a systematic review and meta-analysis of observational studies. Am J Gastroenterol 2011;106:1209–18.
34. Ye X, Liu H, Wu C, et al. Proton pump inhibitors therapy and risk of hip fracture: a systematic review and meta-analysis. Eur J Gastroenterol Hepatol 2011;23:794–800.
35. Vestergaard P, Prieto-Alhambra D, Javaid MK, et al. Fractures in users of antidepressants and anxiolytics and sedatives: effects of age and dose. Osteoporos Int 2013;24:671–80.